CoreD Core D Molecular Virology Core is comprised of an HIV/AIDS DNA sequence analysis component, a BSL-3 virology facility, and microRNA function/RNA interference technologies to serve the evolving needs of basic and clinical translational HIV and associated opportunistic infections research at Duke University.
The specific aims of the Molecular Virology Core are: 1. Provision of Core Services to facilitate the implementation of DNA sequencing, molecular virology assays, and state-of-the-art support for RNA interference and microRNA functional analyses in CFAR laboratories through shared resources in a cost efficient manner. 2. To provide expertise and core resources related to the role of specific human genes in the replication and pathogenesis of HIV-1, opportunistic infections or AIDS-associated malignancies. 3. To stimulate interdisciplinary collaborations between academia and industry to further improve the technology offered by the Core and to provide a solid resource on which collaborations can be fostered. 4. To provide education and training opportunities to CFAR scientists in existing and newly developed virologic methodologies. In order to achieve these aims, the Molecular Virology Core is A) committed to maintaining a high quality of reagents and data through multiple QA/QC procedures and B) establishing a virologic resource that is based on current and future scientific needs of CFAR investigators.
By providing state-of-the-art technical and scientific support for HIV-1 research at Duke and in the wider Research Triangle community, the Molecular Virology Core provides important, and often essential, support for research into novel anti-HIV drugs and into potential HIV vaccine approaches.
|Ramadhani, Habib O; Muiruri, Charles; Maro, Venance P et al. (2017) Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance. AIDS Behav :|
|Han, Qifeng; Williams, Wilton B; Saunders, Kevin O et al. (2017) HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. J Virol 91:|
|Margolis, David M; Koup, Richard A; Ferrari, Guido (2017) HIV antibodies for treatment of HIV infection. Immunol Rev 275:313-323|
|Pollara, Justin; Easterhoff, David; Fouda, Genevieve G (2017) Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS 12:216-221|
|Wang, Kening; Tomaras, Georgia D; Jegaskanda, Sinthujan et al. (2017) Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice J Virol 91:|
|Price, Alexander M; Dai, Joanne; Bazot, Quentin et al. (2017) Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. Elife 6:|
|Martinez, David R; Vandergrift, Nathan; Douglas, Ayooluwa O et al. (2017) Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. J Virol 91:|
|Marks, Florian; von Kalckreuth, Vera; Aaby, Peter et al. (2017) Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health 5:e310-e323|
|Towe, Sheri L; Patel, Puja; Meade, Christina S (2017) The Acceptability and Potential Utility of Cognitive Training to Improve Working Memory in Persons Living With HIV: A Preliminary Randomized Trial. J Assoc Nurses AIDS Care 28:633-643|
|Kelly, Matthew S; Surette, Michael G; Smieja, Marek et al. (2017) The Nasopharyngeal Microbiota of Children With Respiratory Infections in Botswana. Pediatr Infect Dis J 36:e211-e218|
Showing the most recent 10 out of 468 publications